CDMO Valuation Multiples

Healthcare & Life Sciences
Pharma Services Valuation Multiples: CRO, CDMO, EBITDA, and Backlog
ByAuxo Capital AdvisorsJune 19, 2026
A buyer-focused guide to pharma services valuation multiples covering CRO and CDMO pricing, normalized EBITDA, backlog quality, utilization, margins, quality systems, capital needs, buyer fit, deal structure, and seller proceeds.
Read More Pharma Services Valuation Multiples: CRO, CDMO, EBITDA, and Backlog
Healthcare & Life Sciences
CDMO M&A: How Buyers Underwrite Contract Development and Manufacturing Organizations
ByAuxo Capital AdvisorsJune 19, 2026June 19, 2026
A practical buyer-underwriting guide to how CDMOs are evaluated in M&A, with emphasis on utilization, campaign economics, quality and compliance risk, backlog durability, customer concentration, capex needs, valuation adjustments, and purchase-price mechanics.
Read More CDMO M&A: How Buyers Underwrite Contract Development and Manufacturing Organizations